Bayoglu, Ibrahim VedatHuseynov, JavidTopal, AlperSever, NadiyeMajidova, NargizCelebi, AbdussametYasar, Alper2024-06-122024-06-1220232077-0383https://doi.org/10.3390/jcm12196420https://hdl.handle.net/20.500.14551/23198Introduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting. Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan-Meier and Cox regression analysis. Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS. Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.en10.3390/jcm12196420info:eu-repo/semantics/openAccessPNIIMDC ModelPrognosisMetastatic RCCAdjusted PNI-IMDC ModelRenal-Cell-CarcinomaClinical-Practice-GuidelinesSurvivalValidationNephrectomyNivolumabDiagnosisCancerModelsArticle1219N/AWOS:0010836374000012-s2.0-8517385753937835062Q1